Invasive group A streptococcal infections requiring admission to ICU: a nationwide, multicenter, retrospective study (ISTRE study).
ICU mortality
Invasive group A streptococcal infection
Streptococcal toxic shock syndrome intensive care unit
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
received:
21
10
2023
accepted:
08
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
Group A Streptococcus is responsible for severe and potentially lethal invasive conditions requiring intensive care unit (ICU) admission, such as streptococcal toxic shock-like syndrome (STSS). A rebound of invasive group A streptococcal (iGAS) infection after COVID-19-associated barrier measures has been observed in children. Several intensivists of French adult ICUs have reported similar bedside impressions without objective data. We aimed to compare the incidence of iGAS infection before and after the COVID-19 pandemic, describe iGAS patients' characteristics, and determine ICU mortality associated factors. We performed a retrospective multicenter cohort study in 37 French ICUs, including all patients admitted for iGAS infections for two periods: two years before period (October 2018 to March 2019 and October 2019 to March 2020) and a one-year after period (October 2022 to March 2023) COVID-19 pandemic. iGAS infection was defined by Group A Streptococcus isolation from a normally sterile site. iGAS infections were identified using the International Classification of Diseases and confirmed with each center's microbiology laboratory databases. The incidence of iGAS infections was expressed in case rate. Two hundred and twenty-two patients were admitted to ICU for iGAS infections: 73 before and 149 after COVID-19 pandemic. Their case rate during the period before and after COVID-19 pandemic was 205 and 949/100,000 ICU admissions, respectively (p < 0.001), with more frequent STSS after the COVID-19 pandemic (61% vs. 45%, p = 0.015). iGAS patients (n = 222) had a median SOFA score of 8 (5-13), invasive mechanical ventilation and norepinephrine in 61% and 74% of patients. ICU mortality in iGAS patients was 19% (14% before and 22% after COVID-19 pandemic; p = 0.135). In multivariate analysis, invasive mechanical ventilation (OR = 6.08 (1.71-21.60), p = 0.005), STSS (OR = 5.75 (1.71-19.22), p = 0.005), acute kidney injury (OR = 4.85 (1.05-22.42), p = 0.043), immunosuppression (OR = 4.02 (1.03-15.59), p = 0.044), and diabetes (OR = 3.92 (1.42-10.79), p = 0.008) were significantly associated with ICU mortality. The incidence of iGAS infections requiring ICU admission increased by 4 to 5 after the COVID-19 pandemic. After the COVID-19 pandemic, the rate of STSS was higher, with no significant increase in ICU mortality rate.
Sections du résumé
BACKGROUND
BACKGROUND
Group A Streptococcus is responsible for severe and potentially lethal invasive conditions requiring intensive care unit (ICU) admission, such as streptococcal toxic shock-like syndrome (STSS). A rebound of invasive group A streptococcal (iGAS) infection after COVID-19-associated barrier measures has been observed in children. Several intensivists of French adult ICUs have reported similar bedside impressions without objective data. We aimed to compare the incidence of iGAS infection before and after the COVID-19 pandemic, describe iGAS patients' characteristics, and determine ICU mortality associated factors.
METHODS
METHODS
We performed a retrospective multicenter cohort study in 37 French ICUs, including all patients admitted for iGAS infections for two periods: two years before period (October 2018 to March 2019 and October 2019 to March 2020) and a one-year after period (October 2022 to March 2023) COVID-19 pandemic. iGAS infection was defined by Group A Streptococcus isolation from a normally sterile site. iGAS infections were identified using the International Classification of Diseases and confirmed with each center's microbiology laboratory databases. The incidence of iGAS infections was expressed in case rate.
RESULTS
RESULTS
Two hundred and twenty-two patients were admitted to ICU for iGAS infections: 73 before and 149 after COVID-19 pandemic. Their case rate during the period before and after COVID-19 pandemic was 205 and 949/100,000 ICU admissions, respectively (p < 0.001), with more frequent STSS after the COVID-19 pandemic (61% vs. 45%, p = 0.015). iGAS patients (n = 222) had a median SOFA score of 8 (5-13), invasive mechanical ventilation and norepinephrine in 61% and 74% of patients. ICU mortality in iGAS patients was 19% (14% before and 22% after COVID-19 pandemic; p = 0.135). In multivariate analysis, invasive mechanical ventilation (OR = 6.08 (1.71-21.60), p = 0.005), STSS (OR = 5.75 (1.71-19.22), p = 0.005), acute kidney injury (OR = 4.85 (1.05-22.42), p = 0.043), immunosuppression (OR = 4.02 (1.03-15.59), p = 0.044), and diabetes (OR = 3.92 (1.42-10.79), p = 0.008) were significantly associated with ICU mortality.
CONCLUSION
CONCLUSIONS
The incidence of iGAS infections requiring ICU admission increased by 4 to 5 after the COVID-19 pandemic. After the COVID-19 pandemic, the rate of STSS was higher, with no significant increase in ICU mortality rate.
Identifiants
pubmed: 38167516
doi: 10.1186/s13054-023-04774-2
pii: 10.1186/s13054-023-04774-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Informations de copyright
© 2023. The Author(s).
Références
Stevens DL. Invasive group A Streptococcus infections. Clin Infect Dis. 1992;14:2–13.
doi: 10.1093/clinids/14.1.2
pubmed: 1571429
Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685–94.
doi: 10.1016/S1473-3099(05)70267-X
pubmed: 16253886
Factor SH, Levine OS, Schwartz B, Harrison LH, Farley MM, McGeer A, et al. Invasive group A streptococcal disease: risk factors for adults. Emerg Infect Dis. 2003;9:970–7.
doi: 10.3201/eid0908.020745
pubmed: 12967496
pmcid: 3020599
Björck V, Påhlman LI, Bodelsson M, Petersson A-C, Kander T. Morbidity and mortality in critically ill patients with invasive group A Streptococcus infection: an observational study. Crit Care. 2020;24:302.
doi: 10.1186/s13054-020-03008-z
pubmed: 32505194
pmcid: 7275847
Avire NJ, Whiley H, Ross K. A review of Streptococcus pyogenes: public health risk factors. Prevent Control Pathog. 2021;10:248.
Sartelli M, Malangoni MA, May AK, Viale P, Kao LS, Catena F, et al. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. World J Emerg Surg. 2014;9:57.
doi: 10.1186/1749-7922-9-57
pubmed: 25422671
pmcid: 4242587
Babiker A, Li X, Lai YL, Strich JR, Warner S, Sarzynski S, et al. Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study. Lancet Infect Dis. 2021;21:697–710.
doi: 10.1016/S1473-3099(20)30523-5
pubmed: 33333013
Senda A, Endo A, Fushimi K, Otomo Y. Effectiveness of intravenous immunoglobulin therapy for invasive group A Streptococcus infection: a Japanese nationwide observational study. Int J Infect Dis. 2023;135:84–90.
doi: 10.1016/j.ijid.2023.08.011
pubmed: 37586661
Cortés-Penfield N, Ryder JH. Should linezolid replace clindamycin as the adjunctive antimicrobial of choice in group a streptococcal necrotizing soft tissue infection and toxic shock syndrome? A focused debate. Clin Infect Dis. 2023;76:346–50.
doi: 10.1093/cid/ciac720
pubmed: 36056891
Cobo-Vázquez E, Aguilera-Alonso D, Carbayo T, Figueroa-Ospina LM, Sanz-Santaeufemia F, Baquero-Artigao F, et al. Epidemiology and clinical features of Streptococcus pyogenes bloodstream infections in children in Madrid, Spain. Eur J Pediatr. 2023. https://doi.org/10.1007/s00431-023-04967-5 .
doi: 10.1007/s00431-023-04967-5
pubmed: 37889290
Holdstock V, Twynam-Perkins J, Bradnock T, Dickson EM, Harvey-Wood K, Kalima P, et al. National case series of group A Streptococcus pleural empyema in children: clinical and microbiological features. Lancet Infect Dis. 2023;23:154–6.
doi: 10.1016/S1473-3099(23)00008-7
pubmed: 36634683
Okamoto S, Nagase S. Pathogenic mechanisms of invasive group A Streptococcus infections by influenza virus-group A Streptococcus superinfection: invasive GAS infection by superinfection. Microbiol Immunol. 2018;62:141–9.
doi: 10.1111/1348-0421.12577
pubmed: 29377225
Gier B, Vlaminckx BJM, Woudt SHS, Sorge NM, Asten L. Associations between common respiratory viruses and invasive group A streptococcal infection: a time-series analysis. Influ Other Respir Viruses. 2019;13:453–8.
doi: 10.1111/irv.12658
Infection invasive à streptocoque du Groupe A : point de situation épidémiologique au 26 mars 2023. Santé Publique France. https://www.santepubliquefrance.fr/les-actualites/2023/infection-invasive-a-streptocoque-du-groupe-a-point-de-situation-epidemiologique-au-26-mars-2023 .
Nielsen H, Storgaard M, Helweg-Larsen J, Larsen L, Jepsen MPG, Hansen BR, et al. Group A Streptococcus meningitis in adults, Denmark. Emerg Infect Dis. 2023;29:1937.
doi: 10.3201/eid2909.230627
pubmed: 37478289
pmcid: 10461673
[Invasive group A streptococcal infections in the Netherlands], Ned Tijdschr Geneeskd. 2023;167:D7118.
Beyersmann J, Gastmeier P, Schumacher M. Incidence in ICU populations: how to measure and report it? Intensive Care Med. 2014;40:871–6.
doi: 10.1007/s00134-014-3279-7
pubmed: 24817028
Cobo-Vázquez E, Aguilera-Alonso D, Carbayo T, Figueroa-Ospina LM, Sanz-Santaeufemia F, Baquero-Artigao F, et al. Epidemiology and clinical features of Streptococcus pyogenes bloodstream infections in children in Madrid, Spain. Eur J Pediatr. 2023;182:3057–62.
doi: 10.1007/s00431-023-04967-5
pubmed: 37140702
Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85:49–61.
doi: 10.1038/ki.2013.444
pubmed: 24284513
Breiman RF. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA. 1993;269:390.
doi: 10.1001/jama.1993.03500030088038
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801.
doi: 10.1001/jama.2016.0287
pubmed: 26903338
pmcid: 4968574
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–84.
doi: 10.1159/000339789
pubmed: 22890468
Boeddha NP, Atkins L, De Groot R, Driessen G, Hazelzet J, Zenz W, et al. Group A streptococcal disease in paediatric inpatients: a European perspective. Eur J Pediatr. 2022;182:697–706.
doi: 10.1007/s00431-022-04718-y
pubmed: 36449079
pmcid: 9709363
Zangarini L, Martiny D, Miendje Deyi VY, Hites M, Maillart E, Hainaut M, et al. Incidence and clinical and microbiological features of invasive and probable invasive streptococcal group A infections in children and adults in the Brussels-Capital Region, 2005–2020. Eur J Clin Microbiol Infect Dis. 2023;42:555–67.
doi: 10.1007/s10096-023-04568-y
pubmed: 36881216
pmcid: 9989989
McMillan DJ, Drèze P-A, Vu T, Bessen DE, Guglielmini J, Steer AC, et al. Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. Clin Microbiol Infect. 2013;19:E222–9.
doi: 10.1111/1469-0691.12134
pubmed: 23464795
pmcid: 4568957
Johannesen TB, Munkstrup C, Edslev SM, Baig S, Nielsen S, Funk T, et al. Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent Streptococcus pyogenes M1 clone, Denmark, 2023. Eurosurveillance. 2023. https://doi.org/10.2807/1560-7917.ES.2023.28.26.2300291 .
doi: 10.2807/1560-7917.ES.2023.28.26.2300291
pubmed: 37382884
pmcid: 10311951
Gouveia C, Bajanca-Lavado MP, Mamede R, Araújo Carvalho A, Rodrigues F, Melo-Cristino J, et al. Sustained increase of paediatric invasive Streptococcus pyogenes infections dominated by M1UK and diverse emm12 isolates, Portugal, September 2022 to May 2023. Eurosurveillance. 2023. https://doi.org/10.2807/1560-7917.ES.2023.28.36.2300427 .
doi: 10.2807/1560-7917.ES.2023.28.36.2300427
pubmed: 37676143
pmcid: 10486195
Van Kempen EB, Bruijning-Verhagen PCJ, Borensztajn D, Vermont CL, Quaak MSW, Janson J-A, et al. Increase in invasive group a streptococcal infections in children in the Netherlands, a survey among 7 hospitals in 2022. Pediatr Infect Dis J. 2023;42:e122–4.
doi: 10.1097/INF.0000000000003810
pubmed: 36728741
Rodriguez-Ruiz JP, Lin Q, Lammens C, Smeesters PR, Van Kleef-van Koeveringe S, Matheeussen V, et al. Increase in bloodstream infections caused by emm1 group A Streptococcus correlates with emergence of toxigenic M1UK, Belgium, May 2022 to August 2023. Eurosurveillance. 2023. https://doi.org/10.2807/1560-7917.ES.2023.28.36.2300422 .
doi: 10.2807/1560-7917.ES.2023.28.36.2300422
pubmed: 37676145
pmcid: 10486196
Li HK, Zhi X, Vieira A, Whitwell HJ, Schricker A, Jauneikaite E, et al. Characterization of emergent toxigenic M1UK Streptococcus pyogenes and associated sublineages. Microb Genomics. 2023. https://doi.org/10.1099/mgen.0.000994 .
doi: 10.1099/mgen.0.000994
Herrera AL, Huber VC, Chaussee MS. The association between invasive group a streptococcal diseases and viral respiratory tract infections. Front Microbiol. 2016. https://doi.org/10.3389/fmicb.2016.00342/abstract .
doi: 10.3389/fmicb.2016.00342/abstract
pubmed: 28066341
pmcid: 5167725
on behalf of the PAEDS investigators, Oliver J, Thielemans E, McMinn A, Baker C, Britton PN, et al. Invasive group A Streptococcus disease in Australian children: 2016 to 2018—a descriptive cohort study. BMC Public Health. 2019;19:1750.
Turner CE. Can group A Streptococcus infections be influenced by viruses in the respiratory tract? Lancet Infect Dis. 2022;S1473309922008659.
Cohen R, Levy C, Rybak A, Angoulvant F, Ouldali N, Grimprel E. Immune debt: recrudescence of disease and confirmation of a contested concept. Infect Dis Now. 2023;53:104638.
doi: 10.1016/j.idnow.2022.12.003
pubmed: 36535583
Arabi YM, Azoulay E, Al-Dorzi HM, Phua J, Salluh J, Binnie A, et al. How the COVID-19 pandemic will change the future of critical care. Intensive Care Med. 2021;47:282–91.
doi: 10.1007/s00134-021-06352-y
pubmed: 33616696
pmcid: 7898492
Azoulay E, De Waele J, Ferrer R, Staudinger T, Borkowska M, Povoa P, et al. Symptoms of burnout in intensive care unit specialists facing the COVID-19 outbreak. Ann Intensive Care. 2020;10:110.
doi: 10.1186/s13613-020-00722-3
pubmed: 32770449
pmcid: 7414284
Kadambari S, Goldacre R, Morris E, Goldacre MJ, Pollard AJ. Indirect effects of the covid-19 pandemic on childhood infection in England: population based observational study. BMJ. 2022;376:067519.
Carapetis JR, Jacoby P, Carville K, Ang S-JJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis. 2014;59:358–65.
doi: 10.1093/cid/ciu304
pubmed: 24785239